[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342616-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342616-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hla-class-ii-restricted-tcr-targeting-human-papillomavirus-type-18-e7-induces-solid-tumor-remission-in-mice","HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice","","TCR-engineered T cell therapy is promising for solid tumors, yet clinically effective TCR molecules are difficult to obtain. A strategy is presented to clone tumor-specific TCRs from long-term surviving patients who responded to immunotherapy. A HLA-DRA/DRB1*09:01-restricted HPV18 E7(84-98)-specific TCR (10F04) is identified from a MASCT-beneﬁted metastatic cervical cancer patient. After transduction, 10F04 TCR shows robust in vitro and in vivo antitumor activity, redirecting both CD4+ and CD8+ T cells and inducing durable cytokine secretion with strong safety, now under phase I testing for HPV18-positive cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hla-class-ii-restricted-tcr-targeting-human-papillomavirus-type-18-e7-induces-solid-tumor-remission-in-mice/342616/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hla-class-ii-restricted-tcr-targeting-human-papillomavirus-type-18-e7-induces-solid-tumor-remission-in-mice/342616.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What tumor target and HLA restriction are used in the identified TCR?","Question",{"text":63,"@type":64},"The study identifies a TCR (10F04) that is restricted to HLA-DRA/DRB1*09:01 and specifically targets human papillomavirus type 18 (HPV18) E7(84-98).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the 10F04 TCR perform after being engineered into human T cells?",{"text":68,"@type":64},"After transduction, 10F04 TCR demonstrates robust antitumor activity in vitro and in vivo. It redirects both CD4+ and CD8+ T cells to recognize tumor cells and induces multiple cytokine secretion with durable activity and a favorable safety profile.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is HLA class II-restricted TCR-T therapy highlighted as a cancer treatment option?",{"text":72,"@type":64},"The document emphasizes that most clinical-stage TCR-T therapies are HLA-I restricted CD8 TCRs, while accumulating evidence supports HLA-II restricted TCR-transduced CD4 T cells or CD4 tumor-infiltrating lymphocytes as promising for malignant cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342616,1790463704,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article [https://doi.org/10.1038/s41467-024-46558-4](https://doi.org/10.1038/s41467-024-46558-4)  \nHLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice  \nReceived: 20 July 2023  \n\n| Accepted: 1 March 2024 |\n| --- |\n| |\n| Check for updates |\n\nJianting Long1,4, Xihe Chen2,4, Mian He3, Shudan Ou2, Yunhe Zhao3, Qingjia Yan2, Minjun Ma2, Jingyu Chen1, Xuping Qin1, Xiangjun Zhou2, Junjun Chu 2  & Yanyan Han 2   \nT cell receptor (TCR)-engineered T cell therapy is a promising potential treatment for solid tumors, with preliminary efﬁcacy demonstrated in clinical trials. However, obtaining clinically effective TCR molecules remains a major challenge. We have developed a strategy for cloning tumor-speciﬁcTCRs from long-term surviving patients who have responded to immunotherapy. Here, we report the identiﬁcation of a TCR (10F04), which is human leukocyte antigen (HLA)-DRA/DRB1*09:01 restricted and human papillomavirus type 18 (HPV18) E784-98 speciﬁc, from a multiple antigens stimulating cellular therapy (MASCT) beneﬁted metastatic cervical cancer patient. Upon transduction into human T cells, the 10F04TCR demonstrated robust antitumor activity in both in vitro and in vivo models. Notably, the TCR effectively redirected both CD4+ and CD8+ T cells to speciﬁcally recognize tumor cells and induced multiple cytokine secretion along with durable antitumor activity and outstanding safety proﬁles. As a result, this TCR is currently being investigated in a phase I clinical trial for treating HPV18-positive cancers. This study provides an approach for developing safe and effective TCR-T therapies, while underscoring the potential of HLA class II-restricted TCR-T therapy as a cancer treatment.  \nCervical cancer is a signiﬁcant global public health concern, ranking asthe second most common malignancy affecting women’s reproductive organs after uterine cancer. It is attributed to high-risk subtypes of human papillomavirus (HPV) infection with more than 95% of cases1. In 2020, there were ~604,000 new cases of cervical cancer, with 342,000 deaths reported worldwide, and 90% of these cases occurred in low-and middle-income countries2. Even in high-income countries, the 5-year survival rate for distant metastatic cervical cancer remains less than 20%, and there has been no signiﬁcant improvement since the 1970s due to the lack of effective treatment options3. Therefore, there is an urgent need to develop therapeutic approaches for late-stage cervical cancer.  \nImmunotherapy, which utilizes the patient’s immune system to recognize and attack cancer cells, has emerged as a rapidly advancing technology in cancer treatment over the past decades. Immune checkpoint inhibitors (ICIs), which block the immunosuppressive CTLA-4 or PD1 signal pathway of T cells, have been approved and widely used for various types of cancers4, including cervical cancer5. While some patients experience remarkable remissions, the overall response rate (ORR) of anti-PD1 monotherapy for PDL1-positive cervical cancer is only 14.3%5. One of the main reasons limiting the therapeutic efﬁciency of ICIs is the lack of pre-existing T cells capable of recognizing and eliminating cancer cells6. Vaccination, as a safe and  \n1Department of Oncology, Cancer Center, The First Afﬁliated Hospital, Sun Yat-sen University, Guangzhou, PR China. 2HRYZ Biotech Co., Guangzhou, PR China. 3Department of Obstetrics and Gynecology, The First Afﬁliated Hospital, Sun Yat-sen University, Guangzhou, PR China. 4These authors contributed equally: Jianting Long, Xihe Chen. e-mail: [chujunjun@shhryz.com](chujunjun@shhryz.com); [hanyanyan@shhryz.com](hanyanyan@shhryz.com)  \nreliable method, can induce speciﬁc T cells not only to prevent HPV infection and HPV-associated cancer7 but also to target existing tumors8,9. The effectiveness of different types of therapeutic cancer vaccines, such as the dendritic cell (DC) vaccine, mRNA vaccine, and peptide vaccine, has be","cbCaiq8Ugb0OiKTH","https://ap.wps.com/l/cbCaiq8Ugb0OiKTH","pdf",1544989,13,"English","# Abstract\n# Background\n## Unmet needs in cervical cancer immunotherapy\n## Limits of checkpoint blockade and rationale for T cell targeting\n# Therapeutic approaches for tumor-specific T cells\n## Vaccination\n## CAR-T and TCR-T for solid tumors\n## Importance of HLA-II restricted CD4 T cell responses\n# MASCT strategy and TCR cloning rationale","[{\"question\":\"What tumor target and HLA restriction are used in the identified TCR?\",\"answer\":\"The study identifies a TCR (10F04) that is restricted to HLA-DRA/DRB1*09:01 and specifically targets human papillomavirus type 18 (HPV18) E7(84-98).\"},{\"question\":\"How does the 10F04 TCR perform after being engineered into human T cells?\",\"answer\":\"After transduction, 10F04 TCR demonstrates robust antitumor activity in vitro and in vivo. It redirects both CD4+ and CD8+ T cells to recognize tumor cells and induces multiple cytokine secretion with durable activity and a favorable safety profile.\"},{\"question\":\"Why is HLA class II-restricted TCR-T therapy highlighted as a cancer treatment option?\",\"answer\":\"The document emphasizes that most clinical-stage TCR-T therapies are HLA-I restricted CD8 TCRs, while accumulating evidence supports HLA-II restricted TCR-transduced CD4 T cells or CD4 tumor-infiltrating lymphocytes as promising for malignant cancers.\"}]","HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | PDF",1790047410,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4da83fd40f5d5a68c850d3d90a590a88.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f43ec8fe3d1f37600195b06ed2325fb.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e6486200b82c09f17cf32624fd91706.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7cc10077a6e3158cc552a02944af2d1.webp",980,1301]